Updated Jul 16, 2026
Schultes Birgit C is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $79K.
Birgit C. Schultes is the Executive Vice President and Chief Scientific Officer at Intellia Therapeutics, Inc., a company specializing in gene-editing technologies. She has been involved in the development of CRISPR/Cas9-based therapeutics aimed at treating genetically defined diseases.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-03-03 | NTLA | Intellia Therapeutics, Inc. | A — Grant or award | 39.2K | $0.00 | |
| 2026-01-07 | NTLA | Intellia Therapeutics, Inc. | S — Open-market sale | 8.5K | $9.21 | $78K |
| 2025-10-01 | NTLA | Intellia Therapeutics, Inc. | S — Open-market sale | 31 | $17.38 | $539 |
Birgit C. Schultes is the Executive Vice President and Chief Scientific Officer at Intellia Therapeutics, Inc., a company specializing in gene-editing technologies. She has been involved in the development of CRISPR/Cas9-based therapeutics aimed at treating genetically defined diseases.…
Recorded transactions: 0 open-market purchases () and 2 open-market sales ($79K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Schultes Birgit C profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.